Workflow
AI生物医药
icon
Search documents
阿斯利康:将进一步深化在华布局构建科学创新生态
Xin Hua Cai Jing· 2025-05-17 03:15
Group 1 - The 2025 Taihu Bay Life and Health Future Conference was held in Wuxi, Jiangsu, where AstraZeneca engaged in innovative collaborations to promote a scientific innovation ecosystem and high-quality industry development [2] - AstraZeneca's China General Manager emphasized Wuxi as a strategic hub for the company's operations in China, aiming to deepen its presence and foster international cooperation to benefit patients globally [2] - AstraZeneca, in collaboration with Wuxi High-tech Zone and Ruijin Hospital, launched the "Ruijin Yangtze River Delta Metabolic Industry Park" to address patient needs in the metabolic field and enhance the synergy between clinical, industrial, and policy aspects [2] Group 2 - AstraZeneca has been operating in China since 1993, focusing on various therapeutic areas and has introduced over 40 innovative drugs to the market [3] - The company has established two of its six global strategic R&D centers in China, with over 200 projects in its Chinese R&D pipeline, aiming to launch 20 global innovative drugs by 2030 [3] - AstraZeneca has partnered with CICC to establish the AstraZeneca CICC Medical Industry Fund, with approximately $550 million under management, investing in 27 Chinese innovative companies [4] Group 3 - AstraZeneca has invested over $1 billion in Wuxi, establishing a production base, a regional packaging center, and a logistics center [4] - A new small molecule drug factory with an investment of $475 million is under construction in Wuxi, which will primarily produce innovative cardiovascular drugs from AstraZeneca's pipeline [4]
阿斯利康参加太湖湾生命健康未来大会,推动创新生态体系建设
Yang Zi Wan Bao Wang· 2025-05-16 11:57
Group 1 - The 2025 Taihu Bay Life and Health Future Conference was held in Wuxi, focusing on "Digital Intelligence Empowerment for a Healthy Future" [1] - AstraZeneca, in collaboration with Wuxi High-tech Zone and Ruijin Hospital Yangtze River Delta Health Research Institute, launched the "Ruijin Yangtze River Delta Metabolic Industry Park" [1] - The newly established "Yangtze River Delta AI Biomedicine Industry Alliance" aims to accelerate the integration of AI and biomedicine, creating a nationally influential innovation platform [1] Group 2 - AstraZeneca's China General Manager emphasized Wuxi as a strategic hub for the company's operations in China, focusing on scientific innovation and sustainable development [2] - The company plans to deepen its presence in China, promoting international cooperation and contributing to the Healthy China 2030 initiative [2]
“长三角AI生物医药产业联盟”正式成立
news flash· 2025-05-16 07:49
Group 1 - The 2025 Taihu Bay Life and Health Future Conference was held in Wuxi with the theme "Empowering the Future with Digital Intelligence" [1] - AstraZeneca, in collaboration with Wuxi High-tech Zone and Ruijin Hospital Yangtze River Delta Health Research Institute, launched the "Ruijin Yangtze River Delta Metabolic Industry Park" [1] - AstraZeneca, along with Peking University Yangtze River Delta Future Technology Life Health Research Institute, Insilico Medicine, and Shanghai Yangtze River Delta Medical Innovation Life Health Industry Foundation, officially established the "Yangtze River Delta AI Biomedicine Industry Alliance" [1]